Breaking News Instant updates and real-time market news.

TGP

Teekay LNG

$14.37

0.4 (2.86%)

, SFLY

Shutterfly

$45.04

1.11 (2.53%)

16:40
05/15/19
05/15
16:40
05/15/19
16:40

Greenlight takes new stake in Teekay LNG Partners, exits Shutterfly, Dillard's

David Einhorn's Greenlight Capital disclosed in an SEC filing its holdings as of March 31, 2019. Greenlight's one new buy during the quarter was Teekay LNG Partners (TGP). Greenlight exited three positions during the quarter, Shutterfly (SFLY), Dillard's (DDS), and Chemours (CC). Greenlight increased its stake in three holdings, including AerCap Holdings (AER). Greenlight reduced its stake in five holdings, including by size of previous position, General Motors (GM), Tempur Sealy (TPX), Ensco Rowan (ESV), Exela Technologies (XELA), and Voya Financial (VOYA). Greenlight's top holdings as of March 31, in order of size, were General Motors, Green Brick Partners (GRBK), AerCap, Consol Coal (CCR), and Ensco Rowan.

TGP

Teekay LNG

$14.37

0.4 (2.86%)

SFLY

Shutterfly

$45.04

1.11 (2.53%)

DDS

Dillard's

$63.37

-0.58 (-0.91%)

CC

Chemours

$23.74

-0.38 (-1.58%)

AER

AerCap

$50.13

-0.125 (-0.25%)

GM

General Motors

$37.37

0.32 (0.86%)

TPX

Tempur Sealy

$61.41

1.445 (2.41%)

ESV

Ensco Rowan

$11.32

-0.19 (-1.65%)

XELA

Exela Technologies

$3.01

0.03 (1.01%)

VOYA

Voya Financial

$52.77

-0.4 (-0.75%)

GRBK

Green Brick

$9.21

0.07 (0.77%)

CCR

Consol Coal

$17.14

-0.115 (-0.67%)

  • 15

    May

  • 15

    May

  • 18

    May

  • 21

    May

  • 22

    May

  • 22

    May

  • 23

    May

  • 23

    May

  • 28

    May

  • 29

    May

  • 31

    May

  • 04

    Jun

  • 05

    Jun

  • 11

    Jun

  • 01

    Aug

TGP Teekay LNG
$14.37

0.4 (2.86%)

01/22/19
01/22/19
UPGRADE
Target $16

Overweight
Teekay LNG upgraded to Overweight following 45% pullback at Morgan Stanley
As previously reported, Morgan Stanley analyst Fotis Giannakoulis upgraded Teekay LNG to Overweight from Equal Weight following the recent selloff, stating that he believes prior consensus distribution expectations were "too lofty," but he now believes consensus estimates are on the low side following revisions lower. After the stock lost 45% of its value in 2018, the risks are now are skewed to the upside, contends Giannakoulis, who lowered his price target on Teekay LNG shares to $16 from $17.50.
01/22/19
MSCO
01/22/19
UPGRADE
MSCO
Overweight
Teekay LNG upgraded to Overweight from Equal Weight at Morgan Stanley
11/28/18
STFL
11/28/18
UPGRADE
Target $20
STFL
Buy
Teekay LNG upgraded to Buy from Hold at Stifel
Stifel analyst Benjamin Nolan upgraded Teekay LNG Partners to Buy with a $20 price target. While the recent distribution increase is not as large as some would have hoped, it enables the partnership to "aggressively attack debt and eventually grow organically," Nolan tells investors in a research note. Further, Teekay announced that a plan to amend its tax structure in order to remove the K-1 filing burden on the units, which opens the door to a broader base of investors as a 1099 filer, says the analyst. He sees "no further overhangs to valuation improvement" and believes Teekay LNG units are "simply too cheap to ignore."
11/21/18
WELS
11/21/18
NO CHANGE
Target $15
WELS
Outperform
Teekay LNG price target lowered to $15 from $22 at Wells Fargo
Wells Fargo analyst Michael Webber lowered his price target for Teekay LNG to $15 from $22 following quarterly results. The analyst reiterates an Outperform rating on the shares.
SFLY Shutterfly
$45.04

1.11 (2.53%)

04/26/19
04/26/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Cleveland-Cliffs (CLF) upgraded to Outperform from Neutral at Credit Suisse with analyst Curt Woodworth saying he sees potential value near $16-$18 once the HBI plant is fully ramped, even with low hot-rolled coil prices at that point in time. 2. Argo Group (ARGO) upgraded to Outperform from Market Perform at William Blair with analyst Adam Klauber saying Argo is beginning to emerge as a long-term midcap growth insurer, Klauber tells investors in a research note. 3. Illinois Tool Works (ITW) upgraded to Neutral from Underweight at JPMorgan with analyst Ann Duignan saying following the company's "solid" Q1 results, downside risk to 2019 earnings estimates "appears limited," with the worst of auto builds and European weakness "likely behind us." 4. The Medicines Co. (MDCO) upgraded to Buy from Neutral at Goldman Sachs while Esperion (ESPR) upgraded to Neutral from Sell. 5. Shutterfly (SFLY) upgraded to Outperform from Market Perform at Raymond James with analyst Aaron Kessler citing stable Consumer segment growth trends and his expectation for improved consumer growth throughout 2019, as well as "very achievable" 2021 EBITDA guidance of $400M-$450M with modest organic growth assumptions and modest Lifetouch synergies baked in. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/26/19
RAJA
04/26/19
UPGRADE
Target $56
RAJA
Outperform
Shutterfly upgraded to Outperform from Market Perform at Raymond James
Raymond James analyst Aaron Kessler upgraded Shutterfly to Outperform from Market Perform with a $56 price target, citing stable Consumer segment growth trends and his expectation for improved consumer growth throughout 2019, as well as "very achievable" 2021 EBITDA guidance of $400M-$450M with modest organic growth assumptions and modest Lifetouch synergies baked in. Additionally, Kessler says he believes valuation is attractive and that the company's ongoing strategic review could serve as a catalyst, with Bloomberg recently reporting interest from private equity firms.
04/26/19
RAJA
04/26/19
UPGRADE
RAJA
Outperform
Shutterfly upgraded to Outperform from Market Perform at Raymond James
02/06/19
AGIS
02/06/19
NO CHANGE
Target $55
AGIS
Buy
Shutterfly investors' 'best bet' is to hang on in hopes for deal, says Aegis
Aegis analyst Victor Anthony said Shutterfly had an "eventful" evening yesterday, as the company reported revenue and adjusted EBITDA that missed his estimates, gave guidance that also missed his and consensus estimates, pushed out its synergy targets, announced the departure of its CEO and announced it had been approached about a potential acquisition and is exploring alternatives. Anthony, who notes that he previously highlighted Shutterfly as a potential acquisition target or the target of activist investors, believes that "the best bet for investors is to hang onto the shares in anticipation of an acquirer stepping in." A financial buyer could pay $60 per share, while a strategic acquirer could pay $70 per share, believes Anthony, who has a Buy rating and $55 price target on Shutterfly shares.
DDS Dillard's
$63.37

-0.58 (-0.91%)

04/22/19
04/22/19
DOWNGRADE
Target $65

Underperform
Dillard's downgraded to Underperform at Wedbush
As previously reported, Wedbush analyst Jen Redding downgraded Dillard's to Underperform from Neutral, with a $65 price target. The analyst cited an increase in first quarter promotions year over year, according to her Promo Tracker, revenue below consensus based on her proprietary Campaign Data Model, coupled with what she views as "unwarranted share price appreciation" of 11% from February 25th to date, which compares to flat performance from the SPSIRE index over the same period. Further, Redding sees shares of Dillard's underperforming the peer group over the next 6 months.
04/22/19
WEDB
04/22/19
DOWNGRADE
WEDB
Underperform
Dillard's downgraded to Underperform from Neutral at Wedbush
03/04/19
JPMS
03/04/19
DOWNGRADE
Target $57
JPMS
Underweight
Dillard's downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Matthew Boss downgraded Dillard's to Underweight from Neutral and lowered his price target for the shares to $57 from $68. The stock has rallied 25% year-to-date and now trade at 20 times estimated fiscal 2020 earnings, or double the mall-based department store/specialty average, Boss tells investors in a research note. Further, the analyst's work suggests a combination of Dillard's-specific top and bottom-line lead indicators are turning negative.
02/26/19
JPMS
02/26/19
NO CHANGE
Target $68
JPMS
Overweight
JPMorgan sees three 'red flags' from Dillard's Q4 results
JPMorgan analyst Matthew Boss raised his price target for Dillard's to $68 from $61 following the company's Q4 results but keeps a Neutral rating on the shares. The combination of better than expected comps, 16% bottom-line beat, and 64% short interest likely will send the stock higher today, Boss tells investors in a post-earnings research note. However, he sees three "red flags of forward focus" from inventory, the service charge and the reduced amount of share buybacks in Q4 relative to Q3.
CC Chemours
$23.74

-0.38 (-1.58%)

05/06/19
RBCM
05/06/19
NO CHANGE
Target $43
RBCM
Outperform
Chemours price target lowered to $43 from $50 at RBC Capital
RBC Capital analyst Arun Viswanathan lowered his price target on Chemours to $43 after its Q1 earnings miss and "slightly bearish" management outlook for Q2. The analyst also warns that the performance in the Fluoroproducts segment could be similar in Q2 as in Q1 despite the management's forecast of improvement given the softer base refrigerant demand in North America. Viswanathan keeps his Outperform rating however and believes that titanium dioxide volumes could improve in the back half of 2019 as destocking activity runs its course.
05/15/19
RHCO
05/15/19
NO CHANGE
RHCO
Buy
PFAS liability worries for Chemours seem 'premature,' says SunTrust
SunTrust analyst James Sheehan said he mainly attributes the 29% decline in Chemours shares since May 3 to worries about the impact of rising tariffs on titanium dioxide, or TiO2. However, he also notes that at the Ira Sohn conference on May 6 a bearish investor made the "sensational claim" that the company faces "$4-$6B" of potential liabilities from per- and polyfluoroalkyls, or PFAS. After speaking with management, Sheehan noted that they said PFAS is a term that combines several distinct products, some of which Chemours has no exposure to. The company utilizes a PFAS product called GenX, said it sees limited related litigation risk and that it believes it is adequately reserved for any potential liabilities, according to Sheehan. Given the lack of specific legal claims against Chemours regarding PFAS, as well as the company's "proactive stance" on going above the existing regulations in eliminating GenX emissions, Sheehan said he believes concerns about PFAS-related liabilities are "premature." He keeps a Buy rating on Chemours with a price target of $52.
05/06/19
JPMS
05/06/19
DOWNGRADE
Target $34
JPMS
Neutral
JPMorgan downgrades Chemours to Neutral, prefers shares of Tronox
JPMorgan analyst Jeffrey Zekauskas downgraded Chemours (CC) to Neutral from Overweight and lowered his price target for the shares to $34 from $40. The company's Q1 volumes decreased 35% year-over-year, which might be expected in a recession "but it is not any kind of normal result in a growing economy," Zekauskas tells investors in a research note. The analyst decreased his EBITDA expectations, which brought his price target to $34, near the current Chemours share price. He prefers shares of Tronox (TROX) to Chemours.
05/06/19
JPMS
05/06/19
DOWNGRADE
Target $34
JPMS
Neutral
Chemours downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Jeffrey Zekauskas downgraded Chemours to Neutral from Overweight and lowered his price target for the shares to $34 from $40.
AER AerCap
$50.13

-0.125 (-0.25%)

04/08/19
GSCO
04/08/19
INITIATION
Target $58
GSCO
Neutral
AerCap initiated with a Neutral at Goldman Sachs
Goldman Sachs analyst Catherine O'Brien started AerCap Holdings with a Neutral rating and $58 price target. The analyst sees "no upside risk" to consensus estimates for 2019 and 2020 earnings.
03/13/19
MSCO
03/13/19
NO CHANGE
MSCO
Morgan Stanley says 737 MAX grounding shouldn't hurt long-term fundamentals
Morgan Stanley analyst Rajeev Lalwani noted that most major countries and airlines that operate Boeing's (BA) 737 MAX, except for the U.S. and Canada, have placed restrictions around the plane and his expectation is for a grounding of the fleet globally. In that base case, he said there is likely to be disruption to Boeing's deliveries and order activity that ultimately create a buying opportunity over the coming quarters as he thinks the issue should not impact fundamentals in the long run. In regard to suppliers such as Spirit AeroSystems (SPR) and United Technologies (UTX), Lalwani believes disruption will be limited, contrary to market reactions. Among U.S. airlines who operate the 737 MAX, Lalwani said Southwest (LUV) screens as most exposed versus American Airlines (AAL) and United Continental (UAL). For aircraft lessors like Air Lease (AL) and AerCap (AER), a global grounding scenario has "mixed implications," added the analyst. Though he remains comfortable with his Overweight rating and $500 price target on Boeing shares, Lalwani thinks clarity on the path ahead for the 737 will be needed for shares to resume their upward trend.
07/31/18
07/31/18
DOWNGRADE
Target $64

Equal Weight
AerCap downgraded to Equal Weight after outperformance at Stephens
As previously reported, Stephens analyst Vincent Caintic downgraded AerCap (AER) to Equal Weight from Overweight, noting that the stock has outperformed both Air Lease (AL) and Aircastle (AYR) year-to-date. Caintic is finding it more difficult for AerCap to show core EPS growth without "lofty assumptions" and prefers Aer Lease, which he thinks can continue with double-digit EPS growth year-over-year. He maintains a $64 price target on AerCap shares.
07/31/18
SPHN
07/31/18
DOWNGRADE
SPHN
Equal Weight
AerCap downgraded to Equal Weight from Overweight at Stephens
GM General Motors
$37.37

0.32 (0.86%)

05/02/19
NOMU
05/02/19
NO CHANGE
Target $42
NOMU
Neutral
General Motors price target raised to $42 from $36 at Nomura Instinet
Nomura Instinet analyst Anindya Das raised his price target for General Motors to $42 from $36 while keeping a Neutral rating on the shares. In 2019, the analyst expects GM North America to benefit from the extended rollout of the next-generation full-size pickups. However, he sees these gains being partly offset by stiffer competition in the mid-size pickup segment, pricing headwinds for full-size pickups, and volume headwinds from GM's partial withdrawal from the passenger car segment.
05/15/19
05/15/19
NO CHANGE

Trump plans to delay imposing tariffs on auto imports, Bloomberg reports
Publicly traded companies in the space include Daimler AG (DDAIF), Fiat Chrysler (FCAU), Ford (F), General Motors (GM), Honda (HMC), Nissan (NSANY), Toyota (TM), Volkswagen (VWAGY) and Tesla (TLSA).
05/15/19
MSCO
05/15/19
NO CHANGE
MSCO
Tariff delay a 'modest positive' for automakers, says Morgan Stanley
Morgan Stanley analyst Michael Zezas called media reports indicating that the U.S. plans to delay auto tariffs by up to 6 months a "modest positive" for the automaking group, stating that extra time somewhat reduces the probability of tariffs going into place but that the core impasse between the U.S. and EU - namely whether or not to include agricultural issues in negotiations - still remains and is the real driver of the tariff tension. The analyst, who noted that the U.S. retains the option to implement tariffs at any point within the 180 day delay, said he still thinks auto tariffs are likely to go into effect later this year. Publicly traded automakers that moved up following the headlines regarding the delay decision include Daimler AG (DDAIF), Fiat Chrysler (FCAU), Ford (F), General Motors (GM), Honda (HMC), Nissan (NSANY), Toyota (TM) and Volkswagen (VWAGY).
05/01/19
MSCO
05/01/19
NO CHANGE
Target $44
MSCO
Overweight
Morgan Stanley 'sympathetic' to some GM profit taking, keeps Overweight rating
Morgan Stanley analyst Adam Jonas said General Motors' (GM) core Q1 results were "broadly in line" after stripping away the mark-to-market "noise" from the Lyft (LYFT) and PSA revaluations and other factors and he does not see the report materially changing the GM story. While he keeps an Overweight rating on GM shares with a $44 price target, Jonas said he is "sympathetic to some investor profit taking" following the recent run in the stock.
TPX Tempur Sealy
$61.41

1.445 (2.41%)

03/26/19
BOFA
03/26/19
NO CHANGE
Target $75
BOFA
Buy
Tempur Sealy gaining share from biggest rival, says BofA/Merrill
BofA Merrill Lynch analyst Curtis Nagle noted that Bloomberg reported that Serta-Simmons saw its sales decline 15% year-over-year in Q4, which he believes implies that Tempur Sealy gained significant share in the quarter. While "bed-in-a-box" and low-priced Chinese competition could be contributing to Serta-Simmons' declines, it could also be losing share at furniture retailers and independent mattress stores, likely to benefit of Tempur Sealy, Nagle tells investors. The analyst, who added that he continues to see a reconciliation between Tempur Sealy and Mattress Firm as likely, keeps a Buy rating and $75 price target on Tempur Sealy shares.
04/10/19
PIPR
04/10/19
NO CHANGE
Target $68
PIPR
Overweight
Mattress Firm CEO exit makes Tempur reconciliation likely, says Piper Jaffray
The announced resignation of Mattress Firm CEO Steve Stagner significantly increases the likelihood of a Tempur Sealy, Mattress Firm reconciliation in the near future, Piper Jaffray analyst Peter Keith tells investors in a research note. With Steve Stagner departing, the analyst now gives reconciliation a greater than 90% probability and he continues to see $75M of annual EBITDA accretion with reconciliation. While some amount of reconciliation is likely already priced in, Tempur Sealy shares should react "very favorably to this announcement," Keith says. He keeps an Overweight rating on Tempur Sealy with a $68 price target.
04/10/19
WEDB
04/10/19
NO CHANGE
Target $65
WEDB
Outperform
Mattress Firm CEO departure raises probability of Tempur relationship, says Wedbush
Wedbush analyst Seth Basham notes that Mattress Firm has announced that its CEO, Steve Stagner, resigned. The analyst views this as a positive development for Tempur Sealy, as Stagner had a "rocky" relationship with the latter's senior management. With Stagner's resignation, the probability of Tempur Sealy rekindling its distribution relationship with Mattress Firm rises, Basham contends, adding that he estimates that a new agreement could be worth over $100M-plus to run-rate Tempur Sealy EBITDA, with launch costs partly offsetting near-term accretion, and the ramp in sales slower than what it would be if Tempur Sealy were able to get products in Mattress Firm stores before Memorial Day. The analyst reiterates an Outperform rating and $65 price target on Tempur Sealy shares.
05/03/19
RHCO
05/03/19
NO CHANGE
Target $70
RHCO
Hold
Tempur Sealy price target raised to $70 from $53 at SunTrust
SunTrust analyst Keith Hughes raised his price target on Tempur Sealy to $70 after its Q1 earnings beat and raised low end of its prior FY19 EBITDA guidance. The analyst cites the company's "very strong" sales in North America and "no advertising" expense growth in the quarter, though he remains concerned about the impact of anti-dumping tariff on Chinese importers expected in late May. Hughes keeps his Hold rating on Tempur Sealy.
ESV Ensco Rowan
$11.32

-0.19 (-1.65%)

04/16/19
04/16/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Dow Inc. (DOW) initiated with a Top Pick at RBC Capital. 2. Ensco Rowan (ESV) initiated with an Overweight at Morgan Stanley. 3. Micron (MU) initiated with a Neutral at Nomura Instinet. 4. SkyWest (SKYW) initiated with a Buy at Stifel. 5. Forestar Group (FOR) initiated with a Buy at BTIG. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/08/19
HSBC
03/08/19
UPGRADE
HSBC
Buy
Ensco upgraded to Buy from Hold at HSBC
04/11/19
SBSH
04/11/19
INITIATION
Target $4.3
SBSH
Neutral
Ensco resumed with a Neutral at Citi
Citi analyst Scott Gruber resumed coverage of Ensco with a Neutral rating and $4.30 price target. The company is expected to swing to positive free cash flow by 2022, but still needs refinancings to avoid tapping its revolvers, Gruber tells investors in a research note.
04/16/19
MSCO
04/16/19
INITIATION
Target $25
MSCO
Overweight
Ensco Rowan initiated with an Overweight at Morgan Stanley
Following the completion of the merger of Ensco and Rowan to create Ensco Rowan plc, Morgan Stanley analyst Connor Lynagh initiated coverage of the newly combined company with an Overweight rating and $25 price target, noting that analyst estimates vary widely as of now. He believes Ensco Rowan has a strong portfolio of assets and an "undemanding valuation" compared to U.S.-listed peers and sees the discount narrowing as the market gains further clarity.
XELA Exela Technologies
$3.01

0.03 (1.01%)

01/16/19
MSCO
01/16/19
DOWNGRADE
MSCO
Equal Weight
Exela Technologies downgraded to Equal Weight from Overweight at Morgan Stanley
07/30/18
07/30/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. ADMA Biologics (ADMA) initiated with a Buy at Chardan. 2. Alta Mesa Resources (AMR) initiated with a Buy at Guggenheim. 3. Azure Power (AZRE) initiated with an Outperform at JMP Securities. 4. Exela Technologies (XELA) initiated with a Buy at Nomura Instinet. 5. Wix.com (WIX) initiated with a Neutral at Rosenblatt. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/16/19
01/16/19
DOWNGRADE
Target $4.5

Equal Weight
Morgan Stanley downgrades Exela to Equal Weight on limited liquidity, visibility
As previously reported, Morgan Stanley analyst Brian Essex downgraded Exela Technologies (XELA) to Equal Weight from Overweight, stating that a recent cut to guidance for full-year EBITDA gave some investors pause, with no visibility into when the issue may be addressed, and he believes liquidity limits the universe of potential buyers for the stock. He cut his price target on Exela shares to $4.50 from $9.00. In terms of his outlook for the broader IT Services space, Essex said Digital Transformation, Cloud, and Automation are expected to drive healthy demand into 2019. Accenture (ACN) and DXC Technology (DXC) remain his top picks in the space, as he anticipates investor demand for quality, defensive stocks.
10/22/18
MSCO
10/22/18
INITIATION
Target $9
MSCO
Overweight
Exela Technologies initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Brian Essex initiated Exela Technologies with an Overweight rating and $9 price target, stating that the company has established itself as a strong competitor in Business Process Outsourcing that he estimates has been growing at almost twice the rate of the market overall. He sees a pathway for margins in the 20%s with incremental execution and scale, Essex added.
VOYA Voya Financial
$52.77

-0.4 (-0.75%)

03/26/19
FBCO
03/26/19
NO CHANGE
Target $66
FBCO
Outperform
Voya Financial price target raised to $66 from $59 at Credit Suisse
Credit Suisse analyst Andrew Kligerman raised his price target for Voya Financial to $66 from $59 after meeting with the company's management. The analyst notes that management appeared comfortable with 2019-2021 guidance of 10%-plus annual EPS growth and ROE of 13%-15%. Kligerman reiterates an Outperform rating on the shares.
05/09/19
RBCM
05/09/19
NO CHANGE
Target $60
RBCM
Outperform
Voya Financial price target raised to $60 from $55 at RBC Capital
RBC Capital analyst Mark Dwelle raised his price target on Voya Financial to $60 and kept his Outperform rating after its Q1 earnings beat, saying that while the retail investment management flows remained negative, the management discussed a "robust pipeline of new and generally higher fee products." The analyst is positive on the company's prospects for the back half of 2019 and believes that its retirement and investment management business thus far in 2019 has only been constrained by market effects.
01/08/19
01/08/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Voya Financial (VOYA) upgraded to Buy from Neutral at Goldman Sachs analyst Alex Scott saying the company is well positioned to manage through the pullback in equity markets and still hit its targets of 10%-plus earnings growth. 2. Cheesecake Factory (CAKE) upgraded to Outperform from Market Perform at Raymond James with analyst Brian Vaccaro citing better than expected industry sales. 3. Union Pacific (UNP) upgraded to Outperform from Market Perform at Cowen, to Outperform from Sector Perform at RBC Capital and Scotiabank, and to Buy from Neutral at Seaport Global. 4. Monster Beverage (MNST) upgraded to Buy from Hold at SunTrust with analyst William Chappell saying after the recent declines in input costs and the "successful U.S. pricing actions," consensus expectations for the stock are too low, while the concerns over its partnership with Coca-Cola (KO) and challenges around growth in China are "overblown." 5. Molina Healthcare (MOH) upgraded to Overweight from Neutral at both JPMorgan and MUFG. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/05/19
UBSW
02/05/19
DOWNGRADE
Target $45
UBSW
Sell
Principal Financial downgraded to Sell from Neutral at UBS
UBS analyst John Nadel downgraded Principal Financial Group (PFG) to Sell and lowered his price target for the shares to $45 from $46. Consensus estimates remain too high and do not appropriately reflect seasonal weakness typical of Principal's Q1 results, Nadel tells investors in a research note. The analyst views the shares as "currently overvalued" given the company's market pressures in the nearer term and competitive dynamics over the longer term. He prefers shares of Ameriprise Financial (AMP) and Voya Financial (VOYA) to Principal Financial.
GRBK Green Brick
$9.21

0.07 (0.77%)

08/24/18
FBCO
08/24/18
INITIATION
Target $9
FBCO
Neutral
Green Brick initiated with a Neutral at Credit Suisse
Credit Suisse analyst Susan Maklari started Green Brick Partners with a Neutral rating and $9 price target. As supply constraints and inflation persist, the company's margins could be increasingly under pressure, Maklari tells investors in a research note. She believes the current valuation properly captures Green Brick's risk/reward profile.
12/11/18
JPMS
12/11/18
INITIATION
Target $9
JPMS
Neutral
Green Brick initiated with a Neutral at JPMorgan
JPMorgan analyst Michael Rehaut started Green Brick Partners with a Neutral rating and $9 price target. The stock trades in-line to above its smaller-cap homebuilder peers, which is "modestly expensive" on a relative basis given the company's higher geographic concentration and market capitalization at the lower end of its peers, Rehaut tells investors in a research note.
01/24/19
DBAB
01/24/19
INITIATION
Target $10
DBAB
Buy
Green Brick initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Timothy Daley started Green Brick Partners with a Buy rating and $10 price target.
02/06/19
BTIG
02/06/19
INITIATION
BTIG
Neutral
Green Brick initiated with a Neutral at BTIG
BTIG analyst Carl Reichardt initiated Green Brick with a Neutral rating, saying the company has potential for growth but is operating in a challenging environment. The analyst is also positive on Green Brick's private builder acquisitions in less competitive secondary markets of Colorado Springs and Vero Beach plus the launch of a new entry level brand as potential growth catalysts, but warns about "deteriorating demand for the company's mostly move-up product".
CCR Consol Coal
$17.14

-0.115 (-0.67%)

09/11/18
CLKS
09/11/18
DOWNGRADE
CLKS
Consol Coal downgraded to Neutral on valuation at Clarksons Platou
As previously reported, Clarksons Platou downgraded Consol Coal (CCR) to Neutral from Buy and maintained a $21 price target. Analyst Jeremy changed his view saying shares have materially outperformed parent Consol Energy (CEIX), but remain one of his favorite way to play the global thermal coal market.
09/11/18
CLKS
09/11/18
DOWNGRADE
CLKS
Neutral
Consol Coal downgraded to Neutral from Buy at Clarksons Platou

TODAY'S FREE FLY STORIES

TCEHY

Tencent

$0.00

(0.00%)

, MDLA

Medallia

$37.09

(0.00%)

07:31
07/21/19
07/21
07:31
07/21/19
07:31
On The Fly
Opening Day: Start-up DouYou becomes China's biggest Wall Street IPO of 2019 »

Drugmaker Genmab raised…

TCEHY

Tencent

$0.00

(0.00%)

MDLA

Medallia

$37.09

(0.00%)

MIRM

Mirum Pharmaceuticals

$13.51

0.17 (1.27%)

FULC

Fulcrum Therapeutics

$12.49

-0.99 (-7.34%)

PHR

Phreesia

$24.01

-1.15 (-4.57%)

GMAB

Genmab

$18.06

-0.14 (-0.77%)

AMK

AssetMark Financial

$27.71

0.39 (1.43%)

ORCC

Owl Rock

$15.51

0.11 (0.71%)

DOYU

DouYu

$10.50

-0.51 (-4.63%)

NOVA

Sunnova Energy

$0.00

(0.00%)

CSTL

Castle Biosciences

$0.00

(0.00%)

WSG

Wanda Sports

$0.00

(0.00%)

LVGO

Livongo Health

$0.00

(0.00%)

HCAT

Health Catalyst

$0.00

(0.00%)

JNJ

Johnson & Johnson

$130.41

-1.62 (-1.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 22

    Jul

  • 23

    Jul

  • 23

    Jul

  • 24

    Jul

  • 24

    Jul

  • 31

    Jul

  • 14

    Aug

  • 09

    Sep

  • 16

    Sep

  • 15

    Oct

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 26

    Jul

PYPL

PayPal

$118.65

-1.22 (-1.02%)

, V

Visa

$179.18

-1.34 (-0.74%)

08:31
07/20/19
07/20
08:31
07/20/19
08:31
Periodicals
MasterCard, Visa among best stocks to play fintech boom, Barron's says »

The fintech units within…

PYPL

PayPal

$118.65

-1.22 (-1.02%)

V

Visa

$179.18

-1.34 (-0.74%)

MA

MasterCard

$275.51

-1.11 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 24

    Jul

  • 30

    Jul

USB

U.S. Bancorp

$54.98

-0.2 (-0.36%)

, SBNY

Signature Bank

$123.87

1.07 (0.87%)

08:28
07/20/19
07/20
08:28
07/20/19
08:28
Periodicals
KeyCorp, U.S. Bancorp better positioned for Fed rate cut, Barron's says »

KeyCorp (KEY), Signature…

USB

U.S. Bancorp

$54.98

-0.2 (-0.36%)

SBNY

Signature Bank

$123.87

1.07 (0.87%)

KEY

KeyCorp

$17.45

0.15 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 29

    Aug

  • 16

    Oct

CMG

Chipotle

$746.80

-17.43 (-2.28%)

08:24
07/20/19
07/20
08:24
07/20/19
08:24
Periodicals
Chipotle stock made 'stunning' comeback, Barron's says »

Chipotle's stock is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 25

    Sep

BYND

Beyond Meat

$176.65

6.28 (3.69%)

07:40
07/20/19
07/20
07:40
07/20/19
07:40
Periodicals
Beyond Meat could spike after earnings, Barron's says »

After rising so…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jul

NFLX

Netflix

$315.10

-10.04 (-3.09%)

07:37
07/20/19
07/20
07:37
07/20/19
07:37
Periodicals
Netflix's problems have only just begun, Barron's says »

Netflix has a problem and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, TGT

Target

$88.02

-0.48 (-0.54%)

07:34
07/20/19
07/20
07:34
07/20/19
07:34
Periodicals
Time to aim higher on Target's stock, Barron's says »

As retailers have…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

TGT

Target

$88.02

-0.48 (-0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 21

    Aug

  • 19

    Sep

  • 25

    Sep

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, FDX

FedEx

$167.08

1.69 (1.02%)

07:31
07/20/19
07/20
07:31
07/20/19
07:31
Periodicals
FedEx ups game amid e-commerce growth, Barron's says »

It is time to embrace…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

FDX

FedEx

$167.08

1.69 (1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 30

    Jul

  • 31

    Jul

  • 17

    Sep

  • 13

    Nov

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, MSFT

Microsoft

$136.62

0.33 (0.24%)

07:27
07/20/19
07/20
07:27
07/20/19
07:27
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

MSFT

Microsoft

$136.62

0.33 (0.24%)

ORCL

Oracle

$57.55

-0.58 (-1.00%)

AZN

AstraZeneca

$40.11

-0.61 (-1.50%)

BMY

Bristol-Myers

$43.32

-0.72 (-1.63%)

LLY

Eli Lilly

$106.75

-1.57 (-1.45%)

GSK

GlaxoSmithKline

$40.97

-0.44 (-1.06%)

JNJ

Johnson & Johnson

$130.41

-1.62 (-1.23%)

MRK

Merck

$81.39

-1.28 (-1.55%)

NVS

Novartis

$93.58

-0.715 (-0.76%)

PFE

Pfizer

$42.78

-0.28 (-0.65%)

RHHBY

Roche

$0.00

(0.00%)

SNY

Sanofi

$41.94

-0.01 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 24

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 29

    Jul

  • 30

    Jul

  • 30

    Jul

  • 30

    Jul

  • 03

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 27

    Aug

  • 28

    Aug

  • 02

    Sep

  • 09

    Sep

  • 16

    Sep

  • 16

    Sep

  • 20

    Sep

  • 23

    Sep

  • 25

    Sep

  • 02

    Oct

  • 15

    Oct

  • 04

    Nov

BHVN

Biohaven Pharmaceutical

$44.16

-0.61 (-1.36%)

18:12
07/19/19
07/19
18:12
07/19/19
18:12
Hot Stocks
Biohaven receives CRL from FDA for application seeking NURTEC approval »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

CE

Celanese

$107.01

0.9 (0.85%)

18:01
07/19/19
07/19
18:01
07/19/19
18:01
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

F

Ford

$10.20

-0.06 (-0.58%)

17:48
07/19/19
07/19
17:48
07/19/19
17:48
Periodicals
Ford plans to lay off 185 employees at Ontario plant, Reuters reports »

A union local said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 23

    Oct

RTN

Raytheon

$178.55

2.45 (1.39%)

17:48
07/19/19
07/19
17:48
07/19/19
17:48
Hot Stocks
Raytheon awarded $191.01M Air Force contract modification »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

UTX

United Technologies

$132.37

1.08 (0.82%)

17:44
07/19/19
07/19
17:44
07/19/19
17:44
Hot Stocks
United Technologies awarded $253.71M Air Force contract »

United Technologies has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

LMT

Lockheed Martin

$356.90

0.675 (0.19%)

17:40
07/19/19
07/19
17:40
07/19/19
17:40
Hot Stocks
Lockheed Martin awarded $1.47B Missile Defense Agency contract modification »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

ARES

Ares Management

$28.13

-0.305 (-1.07%)

17:33
07/19/19
07/19
17:33
07/19/19
17:33
Syndicate
Breaking Syndicate news story on Ares Management »

Ares Management files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 06

    Aug

HAFC

Hanmi Financial

$21.68

-0.105 (-0.48%)

17:33
07/19/19
07/19
17:33
07/19/19
17:33
Hot Stocks
Hanmi Financial to delay release of Q2 results »

Hanmi Financial announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

PAYS

Paysign

$17.49

-0.48 (-2.67%)

17:32
07/19/19
07/19
17:32
07/19/19
17:32
Syndicate
Breaking Syndicate news story on Paysign »

Paysign files $150M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEOH

Methanex

$43.19

0.83 (1.96%)

17:28
07/19/19
07/19
17:28
07/19/19
17:28
Hot Stocks
Methanex reaches final investment decision on methanol plant in Geismar, LA »

Methanex Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

17:17
07/19/19
07/19
17:17
07/19/19
17:17
Conference/Events
Credit Suisse biotech analysts to hold an analyst/industry conference call »

Biotech Analysts provide…

17:14
07/19/19
07/19
17:14
07/19/19
17:14
Conference/Events
UBS retail/hardlines analyst to hold an analyst/industry conference call »

Retail/Hardlines Analyst…

SHIP

Seanergy Marine

$0.64

-0.0425 (-6.25%)

17:05
07/19/19
07/19
17:05
07/19/19
17:05
Hot Stocks
Seanergy Maritime receives noncompliance notice from Nasdaq »

Seanergy Maritime…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SONM

Sonim

$13.42

0.24 (1.82%)

16:41
07/19/19
07/19
16:41
07/19/19
16:41
Conference/Events
Sonim management to meet with Oppenheimer »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 26

    Jul

  • 12

    Sep

KINS

Kingstone Companies

$8.81

0.09 (1.03%)

16:30
07/19/19
07/19
16:30
07/19/19
16:30
Hot Stocks
Kingstone names Barry Goldstein CEO »

Kingstone Companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 09

    Aug

16:30
07/19/19
07/19
16:30
07/19/19
16:30
Options
Preliminary option volume of 22.6M today »

Preliminary option volume…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.